Several immunomodulatory agents targeting IL-6 and IL-1 blockade were proposed as potential therapeutic options for severe COVID-19 to inhibit the proinflammatory effect and its consequences on pulmonary and other organ function [12,13,14,15,16,17,18,19,20,21]. This evidence concerns the gene IL6 and COVID-19.